Quoin Pharmaceuticals Announces Updated Timing of Third Quarter 2022 Corporate Update Conference Call to be held on Thursday November 10th

Rhea-AI Summary

Quoin Pharmaceuticals Ltd. announced a conference call for its third quarter 2022 business update, scheduled for November 10, 2022, at 10:00 a.m. ET. The call will follow the release of the company's financial results, which will be issued before the market opens on the same day. Investors can participate by calling either 1-877-270-2148 (domestic) or 1-412-902-6510 (international). The live and archived webcast will be accessible on the Quoin Pharmaceuticals website.

Positive

• Scheduled discussion of third quarter 2022 financial results may provide insights into company's performance.
• Focus on rare and orphan diseases indicates a niche market with potential for growth.

Negative

• None.

Conference Call on Thursday November 10, 2022 at 10:00 a.m. ET

ASHBURN, Va., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today updated timing for its third quarter 2022 business update conference call and webcast. The conference call and webcast will now take place at 10:00am ET on Thursday November 10^th, 2022. The third quarter 2022 financial results will be reported before the open of the financial markets on the same day, Thursday November 10, 2022.

The live call can be accessed by dialing 1-877-270-2148 (domestic) or 1-412-902-6510 (international).

The live and archived webcast of the call will be available on the Quoin Pharmaceuticals website under the Investors section: https://investors.quoinpharma.com/news-and-events/events-and-presentations

About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.

For further information, contact:
Investor Relations
PCG Advisory
Stephanie Prince
sprince@pcgadvisory.com
(646) 863-6341

FAQ

What is the date of the Quoin Pharmaceuticals conference call?

The conference call is scheduled for November 10, 2022.

What time will the Quoin Pharmaceuticals conference call occur?

The conference call will take place at 10:00 a.m. ET.

How can I access the Quoin Pharmaceuticals conference call?

The call can be accessed by dialing 1-877-270-2148 (domestic) or 1-412-902-6510 (international).

When will Quoin Pharmaceuticals release its third quarter 2022 financial results?

The financial results will be reported before the market opens on November 10, 2022.

Where can I find the archived webcast of the Quoin Pharmaceuticals call?

The archived webcast will be available on the Quoin Pharmaceuticals website under the Investors section.